Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Non Operating Income (2016 - 2025)

China Pharma Holdings' Non Operating Income history spans 15 years, with the latest figure at -$21940.0 for Q4 2025.

  • For Q4 2025, Non Operating Income rose 22.74% year-over-year to -$21940.0; the TTM value through Dec 2025 reached $51522.0, up 134.93%, while the annual FY2025 figure was $51522.0, 134.93% up from the prior year.
  • Non Operating Income reached -$21940.0 in Q4 2025 per CPHI's latest filing, up from -$23337.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $123753.0 in Q2 2025 to a low of -$332029.0 in Q4 2021.
  • Average Non Operating Income over 5 years is -$69290.2, with a median of -$64161.5 recorded in 2021.
  • Peak YoY movement for Non Operating Income: tumbled 208.77% in 2021, then surged 365.51% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$332029.0 in 2021, then surged by 71.34% to -$95172.0 in 2022, then skyrocketed by 49.86% to -$47722.0 in 2023, then surged by 40.5% to -$28396.0 in 2024, then increased by 22.74% to -$21940.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Non Operating Income are -$21940.0 (Q4 2025), -$23337.0 (Q3 2025), and $123753.0 (Q2 2025).